Skip to main content

Immunic, Inc 10-Q for FY2026 Q3

Immunic, Inc. (IMUX)

10-Q 2026-11-13 For: 2026-09-30
View Original
Added on November 13, 2026

About this 10-Q

Immunic, Inc filed this 10-Q on November 13, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Immunic expects ENSURE top-line data for vidofludimus calcium in December 2026. Cash and cash equivalents of approximately $132.0 million as of September 30, 2026 are expected to fund operations beyond twelve months. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$42.31M
compared with a net loss of $25.58M a year earlier
Diluted EPS
-$0.99
compared with -$1.32 a year earlier